Mark Bodmer and Jonathan Lewis of UCB pharma talk us though the partnering model at UCB, and how partnering can drive innovation. The world is changing and it’s no different for the ...

UCB Pharma has announced that Exemed Pharmaceuticals, a fast-growing Indian manufacturing company, will acquire UCB’S Indian production facility in Vapi. The deal includes a multi-year supply ...

UCB’s head of U.S. immunology Camile Lee said in an interview with Fierce Pharma. Lee also highlighted the drug’s rapid onset of treatment effect and sustained benefits over two years as ...

The transaction involves the sale, divestment, and license of UCB’s mature business (neurology and allergy) in China to CBC ...

it has acquired 100 per cent ownership in the carve-out of UCB Pharma’s mature business in China. UCB, a global biopharmaceutical company headquartered in Belgium, occupies a market-leading ...

United Community Banks, Inc. operates as the financial holding company for United Community Bank that provides financial products and services to commercial, retail, government, education, energy ...

UCB SA has a promising drug, Bimzelx, despite temporary EBITDA decline and potential regulatory hurdles ahead. Learn more ...

Biogen and UCB said Tuesday that an experimental drug reduced disease activity and symptoms of systemic lupus, achieving the primary goal of a placebo-controlled Phase 3 study. Detailed study ...

The University of Manchester and Salford Royal NHS Foundation Trust led studies on Bimekizumab , both published in the prestigious New England Journal of Medicine today, were funded by UCB Pharma; the ...

Barclays analyst Charles Pitman CFA maintained a Buy rating on UCB SA (0NZT – Research Report) today and set a price target of €175.00. The company’s shares closed last Friday at €162.05.

Barclays analyst Charles Pitman CFA maintained a Buy rating on UCB SA (0NZT – Research Report) today and set a price target of €175.00. The company’s shares closed last Friday at €168.20.